Digirad Corporation (NASDAQ:DRAD)‘s stock had its “buy” rating reiterated by research analysts at B. Riley in a research note issued on Thursday. They currently have a $6.00 price objective on the medical equipment provider’s stock. B. Riley’s price target indicates a potential upside of 76.47% from the stock’s previous close.

Separately, Zacks Investment Research upgraded Digirad Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 3rd.

Digirad Corporation (DRAD) opened at 3.40 on Thursday. The firm’s market capitalization is $67.92 million. The stock’s 50 day moving average is $3.49 and its 200-day moving average is $4.16. Digirad Corporation has a 52-week low of $3.15 and a 52-week high of $5.68.

Digirad Corporation (NASDAQ:DRAD) last announced its quarterly earnings results on Friday, August 4th. The medical equipment provider reported $0.08 EPS for the quarter, beating the consensus estimate of $0.03 by $0.05. Digirad Corporation had a positive return on equity of 8.58% and a negative net margin of 2.60%. The company had revenue of $29.79 million for the quarter, compared to the consensus estimate of $30.87 million. Equities analysts expect that Digirad Corporation will post $0.17 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/05/digirad-corporations-drad-buy-rating-reaffirmed-at-b-riley.html.

Institutional investors and hedge funds have recently bought and sold shares of the company. Ancora Advisors LLC boosted its position in shares of Digirad Corporation by 1.6% in the fourth quarter. Ancora Advisors LLC now owns 316,342 shares of the medical equipment provider’s stock valued at $1,582,000 after acquiring an additional 5,000 shares during the period. Cannell Capital LLC boosted its position in shares of Digirad Corporation by 2.5% in the third quarter. Cannell Capital LLC now owns 1,173,901 shares of the medical equipment provider’s stock valued at $5,987,000 after acquiring an additional 28,572 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Digirad Corporation by 5.0% in the first quarter. Goldman Sachs Group Inc. now owns 34,463 shares of the medical equipment provider’s stock valued at $183,000 after acquiring an additional 1,640 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Digirad Corporation by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,065,185 shares of the medical equipment provider’s stock valued at $5,326,000 after acquiring an additional 14,042 shares during the period. Finally, Algert Global LLC boosted its position in shares of Digirad Corporation by 13.1% in the first quarter. Algert Global LLC now owns 31,107 shares of the medical equipment provider’s stock valued at $165,000 after acquiring an additional 3,610 shares during the period. 58.98% of the stock is owned by institutional investors.

About Digirad Corporation

Digirad Corporation provides healthcare solutions. The Company’s segments include Diagnostic Services, Mobile Healthcare, Diagnostic Imaging and Medical Device Sales and Services. Through Diagnostic Services, the Company offers an imaging services program as an alternative to purchasing equipment or outsourcing the procedures to another physician or imaging center.

Receive News & Ratings for Digirad Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad Corporation and related companies with MarketBeat.com's FREE daily email newsletter.